FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARKTM ~ ~ No Clinical Safety or Efficacy Issues Identified; No Additional Studies Required for PEDMARKTM ~ ~ The Company Has Approximately $33 Million in Cash and No Outstanding Debt ~ […]

Read More…

FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR PEDMARK™

Research Triangle Park, NC, September 21, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,792,363 […]

Read More…

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C. USA, August 12, 2020 – Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that Rosty Raykov, Chief Executive Officer of Fennec will present at the following upcoming investor conferences. The following presentations will be webcast live and can be accessed by visiting the investors relations section of the Company’s website at http://investors.fennecpharma.com/events-and-presentations/presentations.  […]

Read More…

Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

~ No Clinical Safety or Efficacy Issues Identified, and No Requirement for Further Clinical Data ~ ~ FDA Pre-Approval Inspection has Identified Deficiencies with the Facility of the Drug Product Manufacturer, which Require Resolution Prior to PEDMARK Approval ~ ~ Company to Host Conference Call and Webcast Today, Tuesday, August 11, 2020, at 8:30 a.m. […]

Read More…

FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~ ~ Strong Financial Position with $38.7 million in cash and no debt ~ Research Triangle Park, NC, August 5, 2020 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation […]

Read More…

FENNEC PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY

Research Triangle Park, NC, June 26, 2020 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced an amendment to its existing senior debt facility with the Life Sciences Group at […]

Read More…

Fennec Announces Results of Annual Meeting

Research Triangle Park, NC — (Marketwired) – June 22, 2020 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 7, 2020 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General […]

Read More…

Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update

~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~ ~ Marketing Authorization Application (MAA) Validated by the EMA in February 2020 ~ ~ Strengthened its Financial Position Through a Raise of Approximately $32 Million in Net Proceeds ~ ~ Commercial Readiness Activities are Underway in the U.S. ~ RESEARCH TRIANGLE PARK, N.C., May 14, 2020 (GLOBE […]

Read More…

Fennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

Research Triangle Park, N.C., May 8, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that in connection with its previously completed underwritten offering […]

Read More…

Fennec Announces Closing of Public Offering

Research Triangle Park, N.C., May 5, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the closing of its previously announced underwritten public offering […]

Read More…